<p>箭头制药（NASDAQ:ARWR - 获取免费报告）在周三发布给客户和投资者的研究报告中，分析师将其目标价从 35.00 美元上调至 46.00 美元，Benzinga 报道。该公司目前对这家生物技术公司的股票给予 “市场表现” 评级。Sanford C. Bernstein 的目标价意味着该公司股价相较于之前收盘价有 41.47% 的潜在下跌空间。</p>
<ul>
<li>想要在生物技术领域获得多元化的上涨机会？查看 LABU</li>
</ul>
<p>其他一些分析师也对该股票发表了看法。B. Riley Financial 在 1 月 22 日的报告中将箭头制药的目标价从 61.00 美元上调至 101.00 美元，并给予该公司 “买入” 评级。摩根大通在 5 月 1 日的报告中开始覆盖箭头制药的股票，给予 “增持” 评级和 88.00 美元的目标价。Piper Sandler 在 1 月 13 日的报告中重申了 “增持” 评级，并将箭头制药的目标价从 100.00 美元上调至 110.00 美元。加拿大皇家银行在 5 月 8 日的报告中将箭头制药的目标价从 80.00 美元上调至 87.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Weiss Ratings 在 5 月 6 日的报告中重申了对箭头制药的 “持有（c-）” 评级。一位研究分析师给予该股票 “强烈买入” 评级，八位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 87.80 美元。</p>
<p><strong>阅读我们关于箭头制药的最新股票报告</strong></p>
<h2>箭头制药的价格表现</h2>
<p>箭头制药的股票在周三的午盘交易中下跌 0.45 美元，达到 78.59 美元。该公司的交易量为 982,488 股，而其平均交易量为 2,587,857 股。该公司的流动比率为 6.23，速动比率为 6.23，债务与股本比率为 1.41。该公司的市值为 110.7 亿美元，市盈率为-36.50，贝塔值为 1.28。该股票的 50 日简单移动平均线为 65.12 美元，200 日简单移动平均线为 61.17 美元。箭头制药的 1 年最低价为 14.30 美元，1 年最高价为 80.67 美元。</p>
<p>箭头制药（NASDAQ:ARWR - 获取免费报告）在 5 月 7 日最后发布了季度财报。这家生物技术公司报告本季度每股收益为-0.93 美元，超出分析师共识预期的-1.10 美元，超出幅度为 0.17 美元。该季度的营业收入为 7374 万美元，而分析师预期为 7384 万美元。箭头制药的净利润率为-48.38%，股本回报率为-55.09%。与去年同期相比，箭头制药的季度收入下降了 86.4%。去年同期，该公司每股收益为 2.75 美元。整体来看，股票研究分析师预测箭头制药在本年度的每股收益将为-3.04 美元。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席财务官 Daniel Joseph Apel 在 4 月 22 日的交易中出售了 13,095 股箭头制药的股票。股票以平均 71.35 美元的价格出售，总交易额为 934,328.25 美元。交易后，首席财务官直接持有该公司 162,905 股股票，价值 11,623,271.75 美元。这笔交易代表了他们持股比例的 7.44% 的减少。该销售在向 SEC 提交的文件中披露，文件可通过此超链接获取。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了覆盖与股权奖励归属相关的税务扣缴义务。此外，内部人士 James C. Hamilton 在 4 月 23 日的交易中出售了 10,000 股箭头制药的股票。该股票以平均 75.00 美元的价格出售，总交易额为 750,000.00 美元。交易后，内部人士直接持有该公司 226,958 股股票，价值约 17,021,850 美元。这代表了他们持股比例的 4.22% 的减少。该销售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去三个月中，内部人士共出售了 33,095 股公司股票，价值 2,326,228 美元。内部人士持有公司股票的比例为 3.60%。</p>
<h2>机构投资者对箭头制药的看法</h2>
<p>机构投资者最近增加或减少了对该股票的持股。Tsfg LLC 在第四季度购买了价值 25,000 美元的箭头制药新股份。First Horizon Corp 在第四季度购买了价值 32,000 美元的箭头制药新股份。WPG Advisers LLC 在第四季度将其在箭头制药的持股增加了 384.8%。WPG Advisers LLC 现在拥有 543 股该生物技术公司的股票，价值 36,000 美元，此前在上个季度又购买了 431 股。Hantz Financial Services Inc.在第四季度将其在箭头制药的持股增加了 177.1%。Hantz Financial Services Inc.现在拥有 737 股该生物技术公司的股票，价值 49,000 美元，此前在上个季度又购买了 471 股。最后，Elyxium Wealth LLC 在第四季度购买了价值 54,000 美元的箭头制药新股份。62.61% 的股票由机构投资者持有。</p>
<h2>关于箭头制药</h2>
<p>（获取免费报告）</p>
<p>Arrowhead Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于 RNA 干扰（RNAi）治疗药物的发现、开发和商业化。自 2008 年成立以来，Arrowhead 利用其专有的递送平台——内部称为先进 RNAi 化合物（ARC）技术——来沉默患有遗传性疾病的患者体内致病基因。该公司的方法旨在提供持久、针对性的治疗，涵盖多个治疗领域。</p>
<p>该公司的产品管线包括多个处于不同开发阶段的候选药物。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Arrowhead Pharmaceuticals 更好的股票</li>
<li>D-Wave 的财报看起来疲软，但投资者可能忽视了这一点</li>
<li>随着 AI 反馈循环加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士卖出</li>
<li>Plug Power 开启盈利模式</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资$1,000 在 Arrowhead Pharmaceuticals 吗？</h2>
<p>在考虑 Arrowhead Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在买入的股票，以便在更广泛的市场注意到之前……而 Arrowhead Pharmaceuticals 并不在名单上。</p>
<p>虽然 Arrowhead Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

箭头制药

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

IBBQ

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

<p>Sanford C. Bernstein 将箭头制药（NASDAQ:ARWR）的目标股价从 35.00 美元上调至 46.00 美元，维持 “市场表现” 评级。这个新目标暗示与前一交易日收盘价相比有 41.47% 的潜在下跌空间。其他分析师的评级和目标股价各不相同，普遍评级为 “适度买入”，平均目标股价为 87.80 美元。箭头制药的股票最近交易价格为 78.59 美元，市值为 110.7 亿美元，净利润率为 -48.38%</p>

<p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) had its price target upped by analysts at Sanford C. Bernstein from $35.00 to $46.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a &#34;market perform&#34; rating on the biotechnology company's stock. Sanford C. Bernstein's price target would indicate a potential downside of 41.47% from the company's previous close.</p>
<div class="lb-trans"><p>箭头制药（NASDAQ:ARWR - 获取免费报告）在周三发布给客户和投资者的研究报告中，分析师将其目标价从 35.00 美元上调至 46.00 美元，Benzinga 报道。该公司目前对这家生物技术公司的股票给予 “市场表现” 评级。Sanford C. Bernstein 的目标价意味着该公司股价相较于之前收盘价有 41.47% 的潜在下跌空间。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技术领域获得多元化的上涨机会？查看 LABU</li>
</ul>
</div><p>A number of other analysts have also weighed in on the stock. B. Riley Financial raised their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, January 22nd. JPMorgan Chase &amp; Co. assumed coverage on shares of Arrowhead Pharmaceuticals in a report on Friday, May 1st. They issued an &#34;overweight&#34; rating and a $88.00 price target for the company. Piper Sandler reaffirmed an &#34;overweight&#34; rating and set a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. Royal Bank Of Canada lifted their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a &#34;hold (c-)&#34; rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $87.80.</p>
<div class="lb-trans"><p>其他一些分析师也对该股票发表了看法。B. Riley Financial 在 1 月 22 日的报告中将箭头制药的目标价从 61.00 美元上调至 101.00 美元，并给予该公司 “买入” 评级。摩根大通在 5 月 1 日的报告中开始覆盖箭头制药的股票，给予 “增持” 评级和 88.00 美元的目标价。Piper Sandler 在 1 月 13 日的报告中重申了 “增持” 评级，并将箭头制药的目标价从 100.00 美元上调至 110.00 美元。加拿大皇家银行在 5 月 8 日的报告中将箭头制药的目标价从 80.00 美元上调至 87.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Weiss Ratings 在 5 月 6 日的报告中重申了对箭头制药的 “持有（c-）” 评级。一位研究分析师给予该股票 “强烈买入” 评级，八位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 87.80 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Arrowhead Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于箭头制药的最新股票报告</strong></p>
</div><h2>Arrowhead Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>箭头制药的价格表现</h2>
</div><p>Shares of Arrowhead Pharmaceuticals stock traded down $0.45 during midday trading on Wednesday, reaching $78.59. The company had a trading volume of 982,488 shares, compared to its average volume of 2,587,857. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $11.07 billion, a price-to-earnings ratio of -36.50 and a beta of 1.28. The stock has a fifty day simple moving average of $65.12 and a 200 day simple moving average of $61.17. Arrowhead Pharmaceuticals has a 1-year low of $14.30 and a 1-year high of $80.67.</p>
<div class="lb-trans"><p>箭头制药的股票在周三的午盘交易中下跌 0.45 美元，达到 78.59 美元。该公司的交易量为 982,488 股，而其平均交易量为 2,587,857 股。该公司的流动比率为 6.23，速动比率为 6.23，债务与股本比率为 1.41。该公司的市值为 110.7 亿美元，市盈率为-36.50，贝塔值为 1.28。该股票的 50 日简单移动平均线为 65.12 美元，200 日简单移动平均线为 61.17 美元。箭头制药的 1 年最低价为 14.30 美元，1 年最高价为 80.67 美元。</p>
</div><p>Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.17. The business had revenue of $73.74 million during the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. Arrowhead Pharmaceuticals's revenue for the quarter was down 86.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.75 earnings per share. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals will post -3.04 earnings per share for the current year.</p>
<div class="lb-trans"><p>箭头制药（NASDAQ:ARWR - 获取免费报告）在 5 月 7 日最后发布了季度财报。这家生物技术公司报告本季度每股收益为-0.93 美元，超出分析师共识预期的-1.10 美元，超出幅度为 0.17 美元。该季度的营业收入为 7374 万美元，而分析师预期为 7384 万美元。箭头制药的净利润率为-48.38%，股本回报率为-55.09%。与去年同期相比，箭头制药的季度收入下降了 86.4%。去年同期，该公司每股收益为 2.75 美元。整体来看，股票研究分析师预测箭头制药在本年度的每股收益将为-3.04 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer directly owned 162,905 shares of the company's stock, valued at $11,623,271.75. This trade represents a 7.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total transaction of $750,000.00. Following the transaction, the insider directly owned 226,958 shares in the company, valued at approximately $17,021,850. This represents a 4.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 33,095 shares of company stock worth $2,326,228. Insiders own 3.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席财务官 Daniel Joseph Apel 在 4 月 22 日的交易中出售了 13,095 股箭头制药的股票。股票以平均 71.35 美元的价格出售，总交易额为 934,328.25 美元。交易后，首席财务官直接持有该公司 162,905 股股票，价值 11,623,271.75 美元。这笔交易代表了他们持股比例的 7.44% 的减少。该销售在向 SEC 提交的文件中披露，文件可通过此超链接获取。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了覆盖与股权奖励归属相关的税务扣缴义务。此外，内部人士 James C. Hamilton 在 4 月 23 日的交易中出售了 10,000 股箭头制药的股票。该股票以平均 75.00 美元的价格出售，总交易额为 750,000.00 美元。交易后，内部人士直接持有该公司 226,958 股股票，价值约 17,021,850 美元。这代表了他们持股比例的 4.22% 的减少。该销售的 SEC 文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去三个月中，内部人士共出售了 33,095 股公司股票，价值 2,326,228 美元。内部人士持有公司股票的比例为 3.60%。</p>
</div><h2>Institutional Investors Weigh In On Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对箭头制药的看法</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the stock. Tsfg LLC bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $25,000. First Horizon Corp bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $32,000. WPG Advisers LLC lifted its position in Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 431 shares in the last quarter. Hantz Financial Services Inc. lifted its position in Arrowhead Pharmaceuticals by 177.1% in the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company's stock valued at $49,000 after acquiring an additional 471 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at $54,000. 62.61% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该股票的持股。Tsfg LLC 在第四季度购买了价值 25,000 美元的箭头制药新股份。First Horizon Corp 在第四季度购买了价值 32,000 美元的箭头制药新股份。WPG Advisers LLC 在第四季度将其在箭头制药的持股增加了 384.8%。WPG Advisers LLC 现在拥有 543 股该生物技术公司的股票，价值 36,000 美元，此前在上个季度又购买了 431 股。Hantz Financial Services Inc.在第四季度将其在箭头制药的持股增加了 177.1%。Hantz Financial Services Inc.现在拥有 737 股该生物技术公司的股票，价值 49,000 美元，此前在上个季度又购买了 471 股。最后，Elyxium Wealth LLC 在第四季度购买了价值 54,000 美元的箭头制药新股份。62.61% 的股票由机构投资者持有。</p>
</div><h2>About Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于箭头制药</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.</p>
<div class="lb-trans"><p>Arrowhead Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于 RNA 干扰（RNAi）治疗药物的发现、开发和商业化。自 2008 年成立以来，Arrowhead 利用其专有的递送平台——内部称为先进 RNAi 化合物（ARC）技术——来沉默患有遗传性疾病的患者体内致病基因。该公司的方法旨在提供持久、针对性的治疗，涵盖多个治疗领域。</p>
</div><p>The company's pipeline includes multiple candidates in various stages of development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同开发阶段的候选药物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li>
<li>Nebius Upside Expands as AI Feedback Loop Intensifies</li>
<li>Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell</li>
<li>Plug Power Flips The Switch On Profitability</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Arrowhead Pharmaceuticals 更好的股票</li>
<li>D-Wave 的财报看起来疲软，但投资者可能忽视了这一点</li>
<li>随着 AI 反馈循环加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士卖出</li>
<li>Plug Power 开启盈利模式</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Arrowhead Pharmaceuticals 吗？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Arrowhead Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在买入的股票，以便在更广泛的市场注意到之前……而 Arrowhead Pharmaceuticals 并不在名单上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arrowhead Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Sanford C. Bernstein Boosts Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $46.00

Market Beat

Invesco Nasdaq Biotechnology ETF

摩根大通

Piper Sandler Cos

加拿大皇家银行

Weis Markets

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存托优先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

桑福德·C·伯恩斯坦将 ArrowHead Pharma（NASDAQ:ARWR）的目标股价上调至 46.00 美元